JP2005508613A - 潜伏中に発現されるマイコバクテリア抗原 - Google Patents

潜伏中に発現されるマイコバクテリア抗原 Download PDF

Info

Publication number
JP2005508613A
JP2005508613A JP2003510686A JP2003510686A JP2005508613A JP 2005508613 A JP2005508613 A JP 2005508613A JP 2003510686 A JP2003510686 A JP 2003510686A JP 2003510686 A JP2003510686 A JP 2003510686A JP 2005508613 A JP2005508613 A JP 2005508613A
Authority
JP
Japan
Prior art keywords
mycobacteria
tuberculosis
gene
peptide
nutrient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003510686A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005508613A5 (https=
Inventor
ウィリアム ジェイムズ，ブライアン
マーシュ，フィリップ
ハンプシャー，トバイアス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Public Health England
Original Assignee
Health Protection Agency
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0116385A external-priority patent/GB0116385D0/en
Priority claimed from GB0123993A external-priority patent/GB0123993D0/en
Application filed by Health Protection Agency filed Critical Health Protection Agency
Publication of JP2005508613A publication Critical patent/JP2005508613A/ja
Publication of JP2005508613A5 publication Critical patent/JP2005508613A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2003510686A 2001-07-04 2002-07-04 潜伏中に発現されるマイコバクテリア抗原 Pending JP2005508613A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0116385A GB0116385D0 (en) 2001-07-04 2001-07-04 Mycobacterial antigens expressed during latency
GB0123993A GB0123993D0 (en) 2001-10-05 2001-10-05 Mycobacterial antigens expressed during latency
PCT/GB2002/003052 WO2003004520A2 (en) 2001-07-04 2002-07-04 Mycobacterial antigens expressed during latency

Publications (2)

Publication Number Publication Date
JP2005508613A true JP2005508613A (ja) 2005-04-07
JP2005508613A5 JP2005508613A5 (https=) 2005-12-22

Family

ID=26246282

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003510686A Pending JP2005508613A (ja) 2001-07-04 2002-07-04 潜伏中に発現されるマイコバクテリア抗原

Country Status (6)

Country Link
US (3) US7393540B2 (https=)
EP (2) EP2196473A1 (https=)
JP (1) JP2005508613A (https=)
AU (2) AU2002314358C1 (https=)
CA (1) CA2453173C (https=)
WO (1) WO2003004520A2 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008543890A (ja) * 2005-06-23 2008-12-04 ステイテンス・セラム・インスティテュート 改良された結核ワクチン
JP2014531896A (ja) * 2011-08-30 2014-12-04 ザ ユーエービー リサーチ ファンデーション ヒト型結核菌ポリンおよび毒素ならびに関連方法
JP2017526742A (ja) * 2014-08-15 2017-09-14 オックスフォード イミュノテック リミテッド 結核菌（Ｍｙｃｏｂａｃｔｅｒｉｕｍ ｔｕｂｅｒｃｕｌｏｓｉｓ）タンパク質
US12234464B2 (en) 2018-11-09 2025-02-25 Ginkgo Bioworks, Inc. Biosynthesis of mogrosides

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9806093D0 (en) * 1998-03-20 1998-05-20 Taylor John Hermon Diagnostics and vaccines for mycobacterial infections of animals and humans
JP2005504523A (ja) 2001-06-22 2005-02-17 ヘルス プロテクション エージェンシー 低酸素圧下で発現するマイコバクテリア抗原
EP2196473A1 (en) 2001-07-04 2010-06-16 Health Protection Agency Mycobacterial antigens expressed during latency
GB0125535D0 (en) * 2001-10-24 2001-12-12 Microbiological Res Authority Mycobacterial genes down-regulated during latency
AU2003242504A1 (en) * 2002-07-13 2004-02-02 Statens Serum Institut Therapeutic tuberculosis vaccines
WO2004067718A2 (en) * 2003-01-24 2004-08-12 Emory University Necrosis-deficient mutants of tuberculosis bacteria
ES2231037B1 (es) 2003-10-31 2005-12-16 Archivel Technologies, Sl Agente inmunoterapico util para el tratamiento combinado de la tuberculosis en asociacion con otros farmacos.
CN101203239B (zh) * 2005-03-31 2014-09-17 莱顿大学医药中心 诊断、预防和治疗分枝杆菌感染和结核疾病的方法和装置
CA2606962A1 (en) * 2005-04-29 2006-11-09 Fusion Antibodies Limited Assays for diagnosis of tuberculosis and uses thereof
US7968694B2 (en) 2005-07-01 2011-06-28 Forsyth Dental Infirmary For Children Tuberculosis antigen detection assays and vaccines
ATE466876T1 (de) * 2005-08-09 2010-05-15 Hav Vaccines Ltd Immunogene konstrukte
US7601357B2 (en) * 2005-12-07 2009-10-13 University Of Central Florida Research Foundation, Inc. Targeting of long chain triacylglycerol hydrolase gene for tuberculosis treatment
CN101378764A (zh) * 2005-12-09 2009-03-04 贝勒研究院 通过血液白细胞微阵列分析对系统性红斑狼疮的诊断、预后和疾病发展的监测
EP1996732A4 (en) * 2006-03-02 2010-03-31 Uab Research Foundation RECOGNITION AND TREATMENT AND DISCOVERY OF REMEDIES AGAINST MYCOBACTERIAL DISEASES
ES2307402B1 (es) 2006-10-30 2009-09-30 Archivel Farma, S.L. Vacuna profilactica contra la tuberculosis.
AP2011005546A0 (en) * 2008-06-25 2011-02-28 Baylor Res Intitute Blood transcriptional signature of mycobacterium tuberculosis infection.
US20110129817A1 (en) * 2009-11-30 2011-06-02 Baylor Research Institute Blood transcriptional signature of active versus latent mycobacterium tuberculosis infection
US20100015171A1 (en) 2008-07-15 2010-01-21 Statens Serum Institute Vaccines comprising tb 10.4
ES2335177B1 (es) 2008-09-19 2011-02-28 Archivel Farma, S.L. Agente inmunoterapeutico apropiado para la profilaxis primaria de la tuberculosis.
WO2011063283A2 (en) 2009-11-20 2011-05-26 Oregon Health & Science University Methods for detecting a mycobacterium tuberculosis infection
GB201008512D0 (en) * 2010-05-21 2010-07-07 Health Prot Agency Mycobacterial antigen composition
ITRM20100411A1 (it) * 2010-07-23 2012-01-24 Massimo Amicosante Uso di sequenze amminoacidiche da mycobacterium tuberculosis o dei loro corrispondenti acidi nucleici per la diagnosi e la prevenzione di infezione tubercolare, relativo kit diagnostico e vaccino.
EP2471511A1 (en) 2011-01-04 2012-07-04 Archivel Farma, SL Liposome formulation suitable for treating or preventing tuberculosis
EP2661253B1 (en) 2011-01-04 2017-04-19 Archivel Farma, SL Liposome formulation suitable for treating or preventing tuberculosis
WO2012138754A2 (en) * 2011-04-04 2012-10-11 Beth Israel Deaconess Medical Center, Inc. Mycobacterial vaccine vectors and methods of using the same
US10703784B2 (en) * 2011-09-30 2020-07-07 La Jolla Institute For Allergy And Immunology Antigens and epitopes derived from Mycobacterium tuberculosis
US20140349320A1 (en) * 2011-12-15 2014-11-27 The Trustees Of The University Of Pennsylvania Using Adaptive Immunity to Detect Drug Resistance
CN104640564B (zh) 2012-07-10 2020-08-04 特兰斯吉恩股份有限公司 分枝杆菌抗原疫苗
WO2014210327A1 (en) * 2013-06-27 2014-12-31 The Brigham And Women's Hospital, Inc. Methods and systems for determining m. tuberculosis infection
EP3092000A1 (en) 2014-01-09 2016-11-16 Transgene SA Fusion of heterooligomeric mycobacterial antigens
GB201400819D0 (en) * 2014-01-17 2014-03-05 Sec Dep For Health The Mycobacterial antigen composition
CN108267588B (zh) * 2016-12-30 2020-10-23 首都医科大学附属北京胸科医院 结核分枝杆菌蛋白在制备诊断结核潜伏感染者和/或活动性肺结核产品中的用途
CN110129465B (zh) * 2019-05-22 2023-08-22 杭州优思达生物技术股份有限公司 一种海分枝杆菌核酸的快速检测方法及其试剂盒

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9024320D0 (en) 1990-11-08 1990-12-19 Univ London Treatment of uveitis
DE4221858A1 (de) 1992-07-03 1994-01-05 Becker Carl Chemie Gmbh Addukte von 0,0-Dialkyldithiophosphorsäuren an ungesättigte Verbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung als Schmiermitteladditive
US6583266B1 (en) * 1993-08-19 2003-06-24 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to mycobacterium tuberculosis and leprae for diagnostics and therapeutics
US5783386A (en) 1994-02-24 1998-07-21 Agresearch, New Zealand Pastoral Agriculture Research Institute Ltd. Mycobacteria virulence factors and a novel method for their identification
KR20060099543A (ko) 1994-12-09 2006-09-19 임페리얼 컬리지 이노베이션스 리미티드 유전자의 동정
US6572865B1 (en) * 1995-06-15 2003-06-03 University Of Victoria Innovation And Development Corporation Mycobacterium tuberculosis DNA sequences encoding immunostimulatory peptides and methods for using same
US5998194A (en) * 1995-12-21 1999-12-07 Abbott Laboratories Polyketide-associated sugar biosynthesis genes
CA2197524A1 (en) * 1996-02-22 1997-08-22 Bradley Stuart Dehoff Polyketide synthase genes
WO1997035611A1 (en) 1996-03-27 1997-10-02 The Johns-Hopkins University Stationary phase, stress response sigma factor from mycobacterium tuberculosis, and regulation thereof
CZ126699A3 (cs) 1996-10-11 1999-09-15 Corixa Corporation Polypeptid obsahující antigenní část rozpustného antigenu M. tuberculosis nebo variantu uvedeného antigenu, molekula DNA kódující tento polypeptid, expresivní vektor, hostitelská buňka, způsoby diagnostiky infekce M. tuberculosis a diagnostické kity
US6555653B2 (en) 1997-05-20 2003-04-29 Corixa Corporation Compounds for diagnosis of tuberculosis and methods for their use
GB9711389D0 (en) 1997-06-04 1997-07-30 Univ Wales The Bacterial pheromones and uses therefor
EP1003870A1 (en) 1997-07-16 2000-05-31 Institut Pasteur A polynucleotide functionally coding for the lhp protein from mycobacterium tuberculosis, its biologically active derivative fragments, as well as methods using the same
WO1999010536A1 (en) 1997-08-22 1999-03-04 Yale University A process to study changes in gene expression in granulocytic cells
GB9723630D0 (en) 1997-11-07 1998-01-07 Stanford Rook Ltd M.vaccae preparation and its use
US6183957B1 (en) * 1998-04-16 2001-02-06 Institut Pasteur Method for isolating a polynucleotide of interest from the genome of a mycobacterium using a BAC-based DNA library application to the detection of mycobacteria
EP1075485A4 (en) 1998-05-05 2004-12-15 Gene Logic Inc METHOD FOR EXAMINING GENE EXPRESSION IN T LYMPHOCYTES
US6892139B2 (en) * 1999-01-29 2005-05-10 The Regents Of The University Of California Determining the functions and interactions of proteins by comparative analysis
GB9904773D0 (en) 1999-03-02 1999-04-28 Microbiological Res Authority Culture of mycobacteria
US6573361B1 (en) * 1999-12-06 2003-06-03 Monsanto Technology Llc Antifungal proteins and methods for their use
US6613553B1 (en) * 2000-02-04 2003-09-02 St. Jude Children's Research Hospital Enoyl reductases and methods of use thereof
AU2002306849A1 (en) 2001-03-21 2002-10-08 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
JP2005504523A (ja) 2001-06-22 2005-02-17 ヘルス プロテクション エージェンシー 低酸素圧下で発現するマイコバクテリア抗原
EP2196473A1 (en) 2001-07-04 2010-06-16 Health Protection Agency Mycobacterial antigens expressed during latency
GB0125535D0 (en) 2001-10-24 2001-12-12 Microbiological Res Authority Mycobacterial genes down-regulated during latency

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008543890A (ja) * 2005-06-23 2008-12-04 ステイテンス・セラム・インスティテュート 改良された結核ワクチン
JP2013121959A (ja) * 2005-06-23 2013-06-20 Statens Serum Inst 改良された結核ワクチン
JP2014531896A (ja) * 2011-08-30 2014-12-04 ザ ユーエービー リサーチ ファンデーション ヒト型結核菌ポリンおよび毒素ならびに関連方法
JP2017526742A (ja) * 2014-08-15 2017-09-14 オックスフォード イミュノテック リミテッド 結核菌（Ｍｙｃｏｂａｃｔｅｒｉｕｍ ｔｕｂｅｒｃｕｌｏｓｉｓ）タンパク質
JP2020198886A (ja) * 2014-08-15 2020-12-17 オックスフォード イミュノテック リミテッド 結核菌（Ｍｙｃｏｂａｃｔｅｒｉｕｍ ｔｕｂｅｒｃｕｌｏｓｉｓ）タンパク質
US12234464B2 (en) 2018-11-09 2025-02-25 Ginkgo Bioworks, Inc. Biosynthesis of mogrosides

Also Published As

Publication number Publication date
US7393540B2 (en) 2008-07-01
AU2008243118A1 (en) 2008-11-27
US20090082296A1 (en) 2009-03-26
US8399650B2 (en) 2013-03-19
AU2002314358B2 (en) 2008-08-14
AU2002314358C1 (en) 2009-03-26
WO2003004520A2 (en) 2003-01-16
EP1404706A2 (en) 2004-04-07
US8003776B2 (en) 2011-08-23
US20120034689A1 (en) 2012-02-09
EP2196473A1 (en) 2010-06-16
CA2453173A1 (en) 2003-01-16
WO2003004520A3 (en) 2003-10-16
US20040241826A1 (en) 2004-12-02
CA2453173C (en) 2013-12-10

Similar Documents

Publication Publication Date Title
US8003776B2 (en) Mycobacterial antigens expressed during latency
US8404826B2 (en) Mycobacterial antigens expressed under low oxygen tension
AU2002314358A1 (en) Mycobacterial antigens expressed during latency
US20110091881A1 (en) Mycobacterial genes down-regulated during latency
AU2002317940A1 (en) Mycobacterial antigens expressed under low oxygen tension
WO1996025519A9 (en) Virulence-attenuating genetic deletions
AU2002336179A1 (en) Mycobacterial genes down-regulated during latency
EP1348036A2 (en) Protection against mycobacterial infections
WO2003033530A2 (en) Mycobacterial antigens expressed under high oxygen tension
US20030171563A1 (en) Regulators of bacterial virulence factor expression
Anwar et al. DNA Vaccine Construct Formation using Mycobacterium-Specific Gene Inh-A

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050412

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050412

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080425

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080528

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080528

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20081009

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090728

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090729

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20090828

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20091113

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20101207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110913

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110922

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111012

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111017

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20111114